TITLE:
Preoperative evaluation of P53 and bcl-2 over expression in clinical stage 1 endometrial carcinoma and their correlation with surgico-pathological data and prognosis of patients
AUTHORS:
Emad A. Fyallah, Reda A. Hemida, Kamal I. Anwar, Nada A. Nadia, Lotfy S. Sherif, Mohammad T. Sayed-Ahmed
KEYWORDS:
Endometrial Carcinoma; Prognosis; P53; Bcl-2
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.1 No.2,
June
30,
2011
ABSTRACT: Introduction: P53 and bcl-2 over expression was reported to affect the biology and prognosis of patients endometrial carcinoma. Methods: This prospective study included 38 patients with histologically confirmed endometrial carcinoma and staged clinically as stage I. Immunohistochemical staining of the tumor specimens obtained by dilatation and curettage (D&C) with P53 and bcl-2 monoclonal antibodies was done. The surgical, pathological and follow up data of all patients were studied. Results: There were 18 cases (47.4%) with positive P53 over expression. P53 over expression was found to be associated with increasing grade of differentiation, advanced stage, and non endometrioid type (significant), and increased depth of myometrial invasion (non-significant). It was associated with more recurrence rate (22% versus 15%) and shorter mean survival time (33.9 versus 29.2 months). Bcl-2 expression was present in24 cases (63.2%) of the studied group. There was significant decrease in bcl-2expression with poorly differentiated, advanced stage, increased depth of myometrial invasion, and non-endometrioid type. It was not significantly correlated with recurrence rate and mean survival time. Conclusion: P53 over expression in the D&C specimens was associated with adverse surgicopathological criteria, increased mortality rate, and shorter survival time in patients with endometrial carcinoma. A significant decrease in bcl-2 expression was associated with adverse surgicopathological criteria, but it was not significantly correlated with prognosis of the patients.